Matches in SemOpenAlex for { <https://semopenalex.org/work/W4302275520> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W4302275520 endingPage "6619" @default.
- W4302275520 startingPage "6608" @default.
- W4302275520 abstract "The renin-angiotensin-aldosterone system (RAAS) activation is the milestone in ascites formation. Hypertonic saline solution (HSS) has attracted considerable interest over the last years in ascites control. Other therapeutic models and concepts have been introduced to overcome diuretic resistance and control ascites. We aimed to evaluate the effects of adding HSS infusion and/or etilefrine to oral diuretics therapy on inflammatory and metabolic pathways, renal and systemic hemodynamics, and clinical outcomes by estimating the changes in selected biochemical and biological markers in cirrhotic patients with ascites.Ninety cirrhotic patients with ascites were studied after administration of HSS infusion (n=25) or etilefrine tablets (n=25), or both (n=25) plus standard diuretics therapy (SDT), or SDT alone (n=15). Serum levels of interleukin-6 (IL-6), aldosterone, leptin, and C-reactive protein (CRP). Hepatic and renal functions were measured at baseline, after eight days, then after 38 days.A significant reduction in serum IL-6, serum aldosterone, Child-Pugh score, MELD-Na score, and increase in serum leptin, and mean arterial pressure (p<0.05) were noted after 38 days in HSS and combination groups. A significant improvement in diuresis, in all groups, urinary sodium excretion, and creatinine clearance (p<0.05) were increased after 38 days in all groups except the SDT group.The results suggest that HSS, etilefrine, and their combination plus SDT are superior to SDT alone for ascites control and can exert some benefits on clinical, systemic, inflammatory, renal, and metabolic pathways without renal or hepatic dysfunction." @default.
- W4302275520 created "2022-10-06" @default.
- W4302275520 creator A5016343836 @default.
- W4302275520 creator A5028641701 @default.
- W4302275520 creator A5031824856 @default.
- W4302275520 creator A5048177062 @default.
- W4302275520 creator A5066409906 @default.
- W4302275520 date "2022-09-01" @default.
- W4302275520 modified "2023-09-27" @default.
- W4302275520 title "Effects of adding hypertonic saline solutions and/or etilefrine to standard diuretics therapy in cirrhotic patients with ascites." @default.
- W4302275520 doi "https://doi.org/10.26355/eurrev_202209_29761" @default.
- W4302275520 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36196711" @default.
- W4302275520 hasPublicationYear "2022" @default.
- W4302275520 type Work @default.
- W4302275520 citedByCount "0" @default.
- W4302275520 crossrefType "journal-article" @default.
- W4302275520 hasAuthorship W4302275520A5016343836 @default.
- W4302275520 hasAuthorship W4302275520A5028641701 @default.
- W4302275520 hasAuthorship W4302275520A5031824856 @default.
- W4302275520 hasAuthorship W4302275520A5048177062 @default.
- W4302275520 hasAuthorship W4302275520A5066409906 @default.
- W4302275520 hasConcept C126322002 @default.
- W4302275520 hasConcept C126894567 @default.
- W4302275520 hasConcept C134018914 @default.
- W4302275520 hasConcept C138976137 @default.
- W4302275520 hasConcept C159641895 @default.
- W4302275520 hasConcept C198710026 @default.
- W4302275520 hasConcept C2777955127 @default.
- W4302275520 hasConcept C2778525890 @default.
- W4302275520 hasConcept C2779547328 @default.
- W4302275520 hasConcept C2779918671 @default.
- W4302275520 hasConcept C2780306776 @default.
- W4302275520 hasConcept C2780496750 @default.
- W4302275520 hasConcept C71924100 @default.
- W4302275520 hasConcept C84393581 @default.
- W4302275520 hasConcept C90924648 @default.
- W4302275520 hasConcept C98274493 @default.
- W4302275520 hasConceptScore W4302275520C126322002 @default.
- W4302275520 hasConceptScore W4302275520C126894567 @default.
- W4302275520 hasConceptScore W4302275520C134018914 @default.
- W4302275520 hasConceptScore W4302275520C138976137 @default.
- W4302275520 hasConceptScore W4302275520C159641895 @default.
- W4302275520 hasConceptScore W4302275520C198710026 @default.
- W4302275520 hasConceptScore W4302275520C2777955127 @default.
- W4302275520 hasConceptScore W4302275520C2778525890 @default.
- W4302275520 hasConceptScore W4302275520C2779547328 @default.
- W4302275520 hasConceptScore W4302275520C2779918671 @default.
- W4302275520 hasConceptScore W4302275520C2780306776 @default.
- W4302275520 hasConceptScore W4302275520C2780496750 @default.
- W4302275520 hasConceptScore W4302275520C71924100 @default.
- W4302275520 hasConceptScore W4302275520C84393581 @default.
- W4302275520 hasConceptScore W4302275520C90924648 @default.
- W4302275520 hasConceptScore W4302275520C98274493 @default.
- W4302275520 hasIssue "18" @default.
- W4302275520 hasLocation W43022755201 @default.
- W4302275520 hasOpenAccess W4302275520 @default.
- W4302275520 hasPrimaryLocation W43022755201 @default.
- W4302275520 hasRelatedWork W112590946 @default.
- W4302275520 hasRelatedWork W1987296894 @default.
- W4302275520 hasRelatedWork W1988630272 @default.
- W4302275520 hasRelatedWork W1995192322 @default.
- W4302275520 hasRelatedWork W2000060815 @default.
- W4302275520 hasRelatedWork W2045169010 @default.
- W4302275520 hasRelatedWork W2093518518 @default.
- W4302275520 hasRelatedWork W2141396386 @default.
- W4302275520 hasRelatedWork W2333991231 @default.
- W4302275520 hasRelatedWork W4302275520 @default.
- W4302275520 hasVolume "26" @default.
- W4302275520 isParatext "false" @default.
- W4302275520 isRetracted "false" @default.
- W4302275520 workType "article" @default.